Friday, Nov 27th

Last update09:59:08 PM GMT

You are here News Health Study outcome won't sway company on eye drug

Study outcome won't sway company on eye drug

E-mail Print PDF

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc., nothing.

The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.


Most Recent Related Stories...

Despite promise, Turing pharmaceuticals opts to keep list price of Daraprim high

Deraprim- Despite a promise from its chief executive two months ago, Turing Pharmaceuticals said Wednesday it...

Federal Court: Restrictive WI Abortion Law Is Unconstitutional, Endangers Women's Health

Wisc. abortion law unconstitutionalA Wisconsin law that requires abortion providers to get admitting privileges at nearby hospitals is unconstitutional,...

Frank Gifford suffered from brain disease CTE, family says

Frank Gifford had CTEPro Football Hall of Famer Frank Gifford, who died this past summer of natural causes, suffered...

CDC says E. coli outbreak linked to Chipotle restaurants now involves six states

Chipolte E.coli outbreak is in six statesAn outbreak of E. coli that was first reported in the Pacific Northwest and linked to...
America's # 1 Enemy
Tee Shirt
& Help Support!
TVNL Tee Shirt
Conserve our Planet
& Help Support!
Get your 9/11 & Media
Deception Dollars
& Help Support!
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!